Nasus Pharma (NSRX) Shares Outstanding (Diluted Average) (2024 - 2025)
Nasus Pharma (NSRX) reported Shares Outstanding (Diluted Average) of $8.0 million for Q4 2025, up 13.98% on a YoY basis from $7.0 million in Q4 2024, and up 4711738.82% quarter-over-quarter from $170.0 in Q2 2025.
Nasus Pharma (NSRX) Shares Outstanding (Diluted Average) (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Shares Outstanding (Diluted Average) for 2 years, with the latest figure at $8.0 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 13.98% year-over-year to $8.0 million; the trailing twelve-month figure through Dec 2025 stood at $8.0 million (up 13.98% YoY), and the FY2025 full-year result was $8.0 million, up 13.98% from the prior year.
- Shares Outstanding (Diluted Average) for Q4 2025 stood at $8.0 million, up from $170.0 in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $8.0 million in Q4 2025, with the low at $170.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 895.90 Mn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.45 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 544.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.25 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 5.73 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Nasus Pharma | 24.83 Mn | 20.55 Mn | - | 8.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.01 Mn |
| Jun 30, 2025 | 170.00 |
| Dec 31, 2024 | 7.03 Mn |